SS Innovations International, Inc. (NASDAQ: SSII), a developer of surgical robotic technologies, has announced the appointment of Sarah M. Romano as its new chief financial officer, effective August 3, 2026. Based in the United States, Romano brings more than two decades of finance leadership experience in the medical technology and life sciences sectors. She will help lead the company’s financial operations as it advances its global expansion strategy, including the pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system.
Romano most recently served as CFO of Vicarious Surgical, where she led financial and operational initiatives to reduce cash burn, strengthen the balance sheet, and support strategic objectives. She previously held CFO roles at Entero Therapeutics and Kiora Pharmaceuticals, where she raised more than $100 million through public and private financings while overseeing strategic transactions, SEC reporting, and investor relations. Her extensive experience in capital markets and corporate finance is expected to be instrumental as SS Innovations scales its operations and seeks regulatory approvals.
SS Innovations develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
The appointment of Romano signals the company’s commitment to strengthening its financial leadership as it navigates the complex regulatory landscape for medical devices. Her track record of raising capital and optimizing financial operations will be critical as SS Innovations prepares for FDA submission and potential commercialization in the U.S. market. The company’s strategy focuses on democratizing robotic surgery by offering lower-cost alternatives to existing systems, which could disrupt the current market dominated by a few key players.
For business and technology leaders, this move highlights the importance of financial expertise in scaling medtech innovations. The surgical robotics market is expected to grow significantly, and companies like SS Innovations that can achieve regulatory approvals while maintaining financial discipline may capture substantial market share. Romano’s appointment also underscores the trend of experienced medtech CFOs moving to emerging growth companies to guide them through critical inflection points.
For more information on the full press release, visit https://ibn.fm/pAqlP. To stay updated on the latest news and updates relating to SSII, visit the company’s newsroom at https://ibn.fm/SSII.
